Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.66 |
| ▸ | TARDBP | Q13148 | 2/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | POLB | P06746 | 1/20 | 0.66 |
| ▸ | THRB | P10828 | 1/20 | 0.66 |
| ▸ | TSHR | P16473 | 1/20 | 0.66 |
| ▸ | ACHE | P22303 | 1/20 | 0.66 |
| ▸ | APEX1 | P27695 | 1/20 | 0.66 |
| ▸ | RECQL | P46063 | 1/20 | 0.66 |
| ▸ | BLM | P54132 | 1/20 | 0.66 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.66 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.66 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17265765 | 1.00 | HSD17B10 (0.66) | HSD17B10KMT2ATARDBPCYP2C9MEN1 | |
| SCHEMBL8521626 | 0.94 | HSD17B10 (0.63) | HSD17B10KMT2ATARDBPCYP2C9MEN1 | |
| SCHEMBL8506279 | 0.94 | HSD17B10 (0.63) | HSD17B10KMT2ATARDBPCYP2C9MEN1 | |
| SCHEMBL17265749 | 0.94 | HSD17B10 (0.63) | HSD17B10KMT2ATARDBPCYP2C9MEN1 | |
| SCHEMBL17265768 | 0.94 | HSD17B10 (0.63) | HSD17B10KMT2ATARDBPCYP2C9MEN1 | |
| SCHEMBL17265758 | 0.92 | HSD17B10 (0.61) | HSD17B10KMT2ATARDBPCYP2C9MEN1 | |
| SCHEMBL10052745 | 0.92 | HSD17B10 (0.61) | HSD17B10KMT2ATARDBPCYP2C9MEN1 | |
| SCHEMBL15249727 | 0.90 | HSD17B10 (0.64) | HSD17B10KMT2ATARDBPCYP2C9MEN1 | |
| SCHEMBL17265766 | 0.90 | HSD17B10 (0.64) | HSD17B10KMT2ATARDBPCYP2C9MEN1 | |
| SCHEMBL6904733 | 0.88 | HSD17B10 (0.52) | HSD17B10KMT2ATARDBPCYP2C9MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4282411-A1 | LIPOYL-GLU-ALA FOR THE TREATMENT OF NEURODEGENERATIVE DAMAGE CAUSED BY TRAUMATIC BRAIN INJURY | Ischemix LLC (US) | 2023-11-29 | — | — | EP | disclosed |
| US-11213509-B2 | Compositions and methods for treating traumatic brain injury | Ischemix, LLC (US) | 2022-01-04 | — | — | US | disclosed |
| US-20200352904-A1 | Compositions And Methods For Treating Traumatic Brain Injury | ISCHEMIX LLC | 2020-11-12 | — | — | US | disclosed |
| US-10744115-B2 | Compositions and methods for treating traumatic brain injury | ISCHEMIX LLC (US) | 2020-08-18 | — | — | US | disclosed |
| EP-2640423-B1 | LIPOYL COMPOUNDS AND THEIR USE FOR TREATING ISCHEMIC INJURY | ISCHEMIX LLC (US) | 2017-07-26 | — | — | EP | disclosed |
| US-9359325-B2 | Lipoyl compounds and methods for treating ischemic injury | ISCHEMIX LLC (US) | 2016-06-07 | — | — | US | disclosed |
| US-20150329519-A1 | Formulations Comprising Lipoyl Compounds | Ischemix, LLC | 2015-11-19 | — | — | US | disclosed |
| WO-2015174948-A1 | FORMULATIONS COMPRISING LIPOYL COMPOUNDS | Ischemix, LLC (US) | 2015-11-19 | — | — | WO | disclosed |
| US-20150065564-A1 | LIPOYL COMPOUNDS AND METHODS FOR TREATING ISCHEMIC INJURY | ISCHEMIX LLC | 2015-03-05 | — | — | US | disclosed |
| US-8815937-B2 | Lipoyl compounds and their use for treating ischemic injury | ISCHEMIX LLC (US) | 2014-08-26 | — | — | US | disclosed |
| US-20130237483-A1 | Lipoyl Compounds And Their Use for Treating Ischemic Injury | ISCHEMIX LLC | 2013-09-12 | — | — | US | disclosed |
| WO-2012067947-A1 | LIPOYL COMPOUNDS AND THEIR USE FOR TREATING ISCHEMIC INJURY | ISCHEMIX LLC (US) | 2012-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11213509-B2 | Compositions and methods for treating traumatic brain injury | BDNF, NLN, FABP7 | HSD17B10 2210/4885KMT2A 1906/4885TARDBP 66/4885 |
| US-20150065564-A1 | LIPOYL COMPOUNDS AND METHODS FOR TREATING ISCHEMIC INJURY | CPT1A, LIPC, LIPG | HSD17B10 311/4885KMT2A 3866/4885TARDBP 4151/4885 |
| US-20200352904-A1 | Compositions And Methods For Treating Traumatic Brain Injury | BDNF, NLN, FABP7 | HSD17B10 2210/4885KMT2A 1906/4885TARDBP 66/4885 |
| US-10744115-B2 | Compositions and methods for treating traumatic brain injury | BDNF, NLN, FABP7 | HSD17B10 2210/4885KMT2A 1906/4885TARDBP 66/4885 |
| US-20130237483-A1 | Lipoyl Compounds And Their Use for Treating Ischemic Injury | CPT1A, LIPG, LIPC | HSD17B10 397/4885KMT2A 4363/4885TARDBP 4210/4885 |
| US-20150329519-A1 | Formulations Comprising Lipoyl Compounds | LIPC, LIPA, DLST | HSD17B10 1428/4885KMT2A 1808/4885TARDBP 4228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.